



BIOHEART

Media Contact: Bioheart, Inc.
13794 NW 4th Street, Suite 212
Sunrise, Florida 33325
Phone: 954.835.1500
bioheart@bioheartinc.com

For Immediate Release

Bioheart Reports Continuing Financial Achievements in First Half and Second Quarter 2015 Results

Sunrise, FL - August 18, 2015 – Bioheart, Inc. (BHRT.OB) announces today its continuing achievements in its first half and second quarter 2015 balance sheet positions and performance results from operations. Of specific note are the following highlights:

- For the six months ended June 30, 2015, the Company's total asset position improved (increased) \$73,066 or 35.6% from its December 31, 2014 balance.
- For the six months ended June 30, 2015, the Company's current liability position improved (decreased) \$2,929,570 or 26.4% from its December 31, 2014 balance.
- For the six months ended June 30, 2015, the Company's total liability position improved (decreased) \$1,661,133 or 14.9% from its December 31, 2014 balance.
- For the six months ending June 30, 2015 versus the same six month period in 2014, product and service revenues increased \$83,444 or 8.5%. Quarter over quarter product and service revenues remained unchanged.
- Inclusive of \$1.98 million in gains on the settlement of debts, the Company reported \$886,594 in net income for the second quarter of 2015 or \$0.001 net income per share.
- For the six months ended June 30, 2015, the Company raised \$764,752 from debt and equity financing activities demonstrating continuing and new investor interest in Bioheart's business plans.

"As demonstrated by our first half and second quarter 2015 financial performance improvements, Bioheart continues to improve its top line revenue performance and balance sheet positions", stated Bioheart President & CEO Mike Tomas. "As we resolve long-standing legacy matters, investor interest in our growth and turn-around plan for the company continues to improve and we feel that our market capitalization value will also begin to rise with the new, common sense investing trends that are being seen in the sector. We are working effectively and efficiently to produce positive results on behalf of our shareholders and we greatly appreciate the positive responses we are receiving. We look forward to reporting additional progress in the second half of 2015."

About Bioheart, Inc.

Bioheart, Inc. is an emerging enterprise in the regenerative medicine / cellular therapy industry. We are focused on the discovery, development and commercialization of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. We believe that regenerative medicine / cellular therapeutics will play a large role in

positively changing the natural history of diseases ultimately, we contend, lessening patient burdens as well as reducing the associated economic impact disease imposes upon modern society.

Our business includes the development of proprietary cell therapy products as well as revenue generating physician and patient based regenerative medicine / cell therapy training services, cell collection and cell storage services, the sale of cell collection and treatment kits for humans and animals, and the operation of a cell therapy clinic. Management maintains that revenues and their associated cash in-flows generated from our businesses will, over time, provide funds to support our clinical development activities as they do today for our general business operations. We believe the combination of our own therapeutics pipeline combined with our revenue generating capabilities provides the Company with a unique opportunity for growth and a pathway to profitability.

US Stem Cell Training, (“SCT”), an operating division of Bioheart, Inc., is a content developer of regenerative medicine / cell therapy informational and training materials for physicians and patients. SCT also provides in-person and online training courses which are delivered through in-person presentations at SCT’s state of the art facilities and globally at university, hospital and physician’s office locations as well as through online webinars. Additionally, SCT provides hands-on clinical application training for physicians and health care professionals interested in providing regenerative medicine / cell therapy procedures.

Vetbiologics, (“VBI”), an operating division of Bioheart, Inc., is a veterinary regenerative medicine company committed to providing veterinarians with the ability to deliver the highest quality regenerative medicine therapies to dogs, cats and horses. VBI provides veterinarians with extensive regenerative medicine capabilities including the ability to isolate regenerative stem cells from a patient’s own adipose (fat) tissue directly on-site within their own clinic or stall-side. VBI regenerative medicine technologies are designed, implemented and produced according to the highest standards. VBI follows the FDA guidelines for human cellular therapy production which means each product produced must be validated and must pass stringent criteria.

US Stem Cell Clinic, LLC, (“SCC”), a partially owned investment of Bioheart, Inc., is a physician run regenerative medicine / cell therapy clinic providing cellular treatments for patients afflicted with neurological, autoimmune, orthopedic and degenerative diseases. SCC is operating in compliance with the FDA 1271s which allow for same day medical procedures to be considered the practice of medicine. We isolate stem cells from bone marrow and adipose tissue and also utilize platelet rich plasma.

Forward-Looking Statements: Except for historical matters contained herein, statements made in this press release are forward-looking statements. Without limiting the generality of the foregoing, words such as “may”, “will”, “to”, “plan”, “expect”, “believe”, “anticipate”, “intend”, “could”, “would”, “estimate”, or “continue”, or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements.

Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date hereof. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

The Company is subject to the risks and uncertainties described in its filings with the Securities and Exchange Commission, including the section entitled “Risk Factors” in its Annual Report on Form 10-K for the year ended December 31, 2014, and its Quarterly Reports on Form 10-Q.